"Medtronic’s PulseSelect system shows lesion durability in Afib treatment" was originally created and published by Medical ...

Medtronic plc MDT has shared late-breaking clinical trial results for its PulseSelect Pulsed Field Ablation (“PFA”) system, demonstrating a high rate of durable lesion formation in treating atrial ...

Medtronic plc (MDT) announced that clinical study results demonstrated a high rate of durable lesion formation using the PulseSelect ...

Medtronic presents positive data from PulseSelect PFA System in treating atrial fibrillation at APHRS meeting: Galway, Ireland Monday, September 30, 2024, 10:00 Hrs [IST] Medtroni ...

(RTTNews) - Medtronic plc (MDT) announced that clinical study results demonstrated a high rate of durable lesion formation using the PulseSelect Pulsed Field Ablation (PFA) System in the treatment ...

Discover why Medtronic is a top Dividend Aristocrat with strong financial performance and potential for 12% annual returns ...

This is attributed to the company's PulseSelect product only partially compensating for the decline in cryogenic ablation sales, despite the advantage of higher average selling prices (ASPs).

Medtronic announced Japanese approval of the competing PulseSelect PFA system in May. “The Farapulse PFA system is the most ...

SHARJAH, 4th September, 2024 (WAM) -- Al Qassimi Hospital in Sharjah, an Emirates Health Services facility, has unveiled the adoption of the cutting-edge "PulseSelect" technology for the treatment of ...